These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

83 related articles for article (PubMed ID: 18360268)

  • 1. Limited benefit of biochemical response to combination therapy for patients with recurrent hepatitis C after living-donor liver transplantation.
    Ueda Y; Takada Y; Haga H; Nabeshima M; Marusawa H; Ito T; Egawa H; Tanaka K; Uemoto S; Chiba T
    Transplantation; 2008 Mar; 85(6):855-62. PubMed ID: 18360268
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of maintenance therapy with low-dose peginterferon for recurrent hepatitis C after living donor liver transplantation.
    Ueda Y; Marusawa H; Kaido T; Ogura Y; Oike F; Mori A; Ogawa K; Yoshizawa A; Hatano E; Miyagawa-Hayashino A; Haga H; Egawa H; Takada Y; Uemoto S; Chiba T
    J Viral Hepat; 2012 Jan; 19(1):32-8. PubMed ID: 21129128
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The benefits of interferon treatment in patients without sustained viral response after living donor liver transplantation for hepatitis C.
    Ikegami T; Taketomi A; Soejima Y; Yoshizumi T; Fukuhara T; Kotoh K; Shimoda S; Kato M; Maehara Y
    Transplant Proc; 2009 Dec; 41(10):4246-52. PubMed ID: 20005378
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antiviral treatment of recurrent hepatitis C after liver transplantation: predictors of response and long-term outcome.
    Selzner N; Renner EL; Selzner M; Adeyi O; Kashfi A; Therapondos G; Girgrah N; Herath C; Levy GA; Lilly L
    Transplantation; 2009 Nov; 88(10):1214-21. PubMed ID: 19935376
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical and histological efficacy of pegylated interferon and ribavirin therapy of recurrent hepatitis C after liver transplantation.
    Fernández I; Meneu JC; Colina F; García I; Muñoz R; Castellano G; Fuertes A; Abradelo M; Lumbreras C; Moreno E; Solís-Herruzo JA
    Liver Transpl; 2006 Dec; 12(12):1805-12. PubMed ID: 17133585
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sustained viral response to interferon and ribavirin in liver transplant recipients with recurrent hepatitis C.
    Abdelmalek MF; Firpi RJ; Soldevila-Pico C; Reed AI; Hemming AW; Liu C; Crawford JM; Davis GL; Nelson DR
    Liver Transpl; 2004 Feb; 10(2):199-207. PubMed ID: 14762857
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combination of interferon alfa-2b and ribavirin in liver transplant recipients with histological recurrent hepatitis C.
    Firpi RJ; Abdelmalek MF; Soldevila-Pico C; Reed A; Hemming A; Howard R; Van Der Werf W; Lauwers G; Liu C; Crawford JM; Davis GL; Nelson DR
    Liver Transpl; 2002 Nov; 8(11):1000-6. PubMed ID: 12424712
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of antiviral therapy on hepatitis C recurrence after liver transplantation: a randomized controlled study.
    Carrión JA; Navasa M; García-Retortillo M; García-Pagan JC; Crespo G; Bruguera M; Bosch J; Forns X
    Gastroenterology; 2007 May; 132(5):1746-56. PubMed ID: 17484872
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prediction of sustained virological response in liver transplant recipients with recurrent hepatitis C virus following combination pegylated interferon alfa-2b and ribavirin therapy using tissue hepatitis C virus reverse transcriptase polymerase chain reaction testing.
    Neff GW; O'Brien CB; Cirocco R; Montalbano M; de Medina M; Ruiz P; Khaled AS; Bejarano PA; Safdar K; Hill MA; Tzakis AG; Schiff ER
    Liver Transpl; 2004 May; 10(5):595-8. PubMed ID: 15108250
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New approaches to the treatment of hepatitis C virus infection after liver transplantation using ribavirin.
    Bizollon T; Ducerf C; Trépo C
    J Hepatol; 1995; 23 Suppl 2():22-5. PubMed ID: 8720290
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of recurrent hepatitis C infection after liver transplantation with combination of pegylated interferon alpha2b and ribavirin: an open-label series.
    Rodriguez-Luna H; Khatib A; Sharma P; De Petris G; Williams JW; Ortiz J; Hansen K; Mulligan D; Moss A; Douglas DD; Balan V; Rakela J; Vargas HE
    Transplantation; 2004 Jan; 77(2):190-4. PubMed ID: 14742979
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of interferon treatment on liver histology and allograft rejection in patients with recurrent hepatitis C following liver transplantation.
    Stravitz RT; Shiffman ML; Sanyal AJ; Luketic VA; Sterling RK; Heuman DM; Ashworth A; Mills AS; Contos M; Cotterell AH; Maluf D; Posner MP; Fisher RA
    Liver Transpl; 2004 Jul; 10(7):850-8. PubMed ID: 15237368
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of patients with recurrent hepatitis C after liver transplantation with peginterferon alfa-2B plus ribavirin.
    Neumann U; Puhl G; Bahra M; Berg T; Langrehr JM; Neuhaus R; Neuhaus P
    Transplantation; 2006 Jul; 82(1):43-7. PubMed ID: 16861940
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recurrent hepatitis C after liver transplantation: on-treatment prediction of response to peginterferon/ribavirin therapy.
    Hanouneh IA; Miller C; Aucejo F; Lopez R; Quinn MK; Zein NN
    Liver Transpl; 2008 Jan; 14(1):53-8. PubMed ID: 18161839
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Successful treatment of hepatitis C reinfection with interferon-alpha2b and ribavirin after liver transplantation.
    Yedibela S; Schuppan D; Müller V; Schellerer V; Tannapfel A; Hohenberger W; Meyer T
    Liver Int; 2005 Aug; 25(4):717-22. PubMed ID: 15998420
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combined treatment with pegylated interferon (alpha-2b) and ribavirin in the acute phase of hepatitis C virus recurrence after liver transplantation.
    Castells L; Vargas V; Allende H; Bilbao I; Luis Lázaro J; Margarit C; Esteban R; Guardia J
    J Hepatol; 2005 Jul; 43(1):53-9. PubMed ID: 15876467
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of low accelerating dose regimen of interferon/ribavirin antiviral therapy in patients with hepatitis C virus recurrence after liver transplantation.
    Su H; Liu Z; Sun Y; Li H; Zhou S; Zhou X; Gao Y; Tang R; Zhang D; Zhang M
    Ann Transplant; 2015 May; 20():263-8. PubMed ID: 25975740
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antiviral therapy for hepatitis C virus recurrence following liver transplantation: long-term results from a single center experience.
    Burra P; Targhetta S; Pevere S; Boninsegna S; Guido M; Canova D; Brolese A; Masier A; D'Aloiso C; Germani G; Tomat S; Fagiuoli S
    Transplant Proc; 2006 May; 38(4):1127-30. PubMed ID: 16757285
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hepatitis C virus therapy in liver transplant recipients: response predictors, effect on fibrosis progression, and importance of the initial stage of fibrosis.
    Roche B; Sebagh M; Canfora ML; Antonini T; Roque-Afonso AM; Delvart V; Saliba F; Duclos-Vallee JC; Castaing D; Samuel D
    Liver Transpl; 2008 Dec; 14(12):1766-77. PubMed ID: 19025933
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of liver steatosis on the antiviral response in the hepatitis C virus-associated chronic hepatitis.
    Soresi M; Tripi S; Franco V; Giannitrapani L; Alessandri A; Rappa F; Vuturo O; Montalto G
    Liver Int; 2006 Nov; 26(9):1119-25. PubMed ID: 17032413
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.